Clinical trial · Interventional
Rasburicase in Tumor Lysis Syndrome
Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.
NCT00302653CI-TRIAL-00002663completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperuricemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rasburicase | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Rasburicase 0,20mg/Kg/Day once a day 3-7 days
- interventionNames
- Drug: Rasburicase
Primary outcomes (3)
- measure
- Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)
- timeFrame
- 24-48 hours after last dose of rasburicase
- measure
- Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)
- timeFrame
- 28 (+- 3) days after the last dose of rasburicase
- measure
- Adverse events occurrence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
List of inclusion Criteria: * Acute hyperuricemia patients(uric acid\>8.0 mg/dl) before/during chemotherapy for hematologic malignancies. List of exclusion Criteria: * Hypersensitivity to uricases or any of the excipients. * Known history of hemolytic anemia (G6PD deficiency). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.